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1. Introduction
Bicuspid aortic valve (BAV) disease is one of the most frequent observed congenital heart
abnormalities affecting 0.5-1.4% of the general population and has a 3:1 male predominance
[1-4]. Although some genes have been described that found to be responsible for the abnormal
valvulogenesis, little is known about BAV disease with respect to the genetic and embryolog‐
ical insight of calcification and why patients with BAV disease develop aortic valve calcifica‐
tion including severe aortic valve stenosis (AS) at an earlier age compared with degenerative
tricuspid valve. BAV disease is also associated with several cardiovascular abnormalities
including coarctation of the aorta (COA) and Turner Syndrome. While patients with BAV
disease are often asymptomatic during the childhood, BAV disease is generally diagnosed in
the adulthood using echocardiography when aortic stenosis with or without valve calcifica‐
tion, infective endocarditis, aortic regurgitation (AR), and proximal thoracic aortic dilatation
are detected, often necessitating surgical intervention [5]. Patients with BAV disease require
close observation before complications as heart failure and aortic dissection may occur. In this
chapter, the contemporary knowledge regarding BAV disease will be discussed.
2. Anatomy and pathology
The anatomic features of BAV are characterized by smooth cusps margins and the fusion of
two cusps of unequal size. These cusps often include a central raphé or false commissure which
are usually in the centre of the larger cusp [Figure 2]. The main difference between a commis‐
sure and a raphé is that the commissure does not completely span into the cusp [6]. The raphé
is to be considered as a hypoplastic commissure between two partially fused cusps. The most
commonly seen variant of BAV is the fusion of the left and right coronary cusps (L-R BAV)
© 2013 Tokmaji et al.; licensee InTech. This is an open access article distributed under the terms of the
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also known as the latero-lateral cusps position which is seen in 70-86% of the BAV cases,
whereas the fusion of the right and noncoronary cusps (R-N BAV; antero-posterior cusps
position) are observed in 12-28% and the left and noncoronary cusps (L-N BAV) in 0.5-3% of
the cases [7-11] [Figure 1]. R-N BAVs and asymmetrical sized cusps are relative risk factors
that seem to accelerate the stenosis with 27 mm Hg per decade and are therefore more often
associated with AS [12]. BAV with equal cusps and absence of raphé have also been reported
[6, 7]. In some cases, the raphé can have a quite deep indentation, which could give a false
echocardiographic image of a normal tricuspid aortic valve [13]. Calcium depositions are often
confined to the raphé and the base of the cusps [7]. AS tend to develop in BAVs which contain
no redundant cusp tissue whereas AR tend to develop in BAVs due to the different dimensions
of the two cusps, valve prolapse or redundancy of one cusp [14-16]. Histological examination
demonstrates that the raphé does not contain fibrous valve tissue but rather include elastin
fibers [17]. BAV should also be distinguished from unicommisural valves that tend to calcify
and degenerate even earlier in life. Unicommissural valves includes one commissure with
normal height and two raphe’s that are much lower height, while there is one large cusp, more
or less moving like a bicuspid valve. Up to 90% of the individuals with normal tricuspid valve
have right coronary artery dominance whereas 29% to 57% of the patients with BAV disease
present with left coronary artery dominance. The average length of the left main stem for
individuals with BAV and tricuspid valve is less than 5 mm (90% of the cases) and 10 mm in
length, respectively. Recognition of these associations with BAV is mandatory due to the
increased risk of perioperative myocardial infarction and a potential risk of insufficient
myocardial preservation at the time of aortic valve replacement (AVR) [18, 19, 20]. L-R BAVs
are often associated with right coronary artery taking its origin from the right sinus of Valsalva,
while in the R-N BAVs, both coronary arteries derive from the anterior sinus [21]. The vast
majority of the patients with COA present with a L-R BAV (66-90%) [9, 135, 136].
Figure 1. Schematic illustration of the anatomic variations of BAV. (A) normal tricuspid aortic valve. (B) Bicuspid aortic
valve, fusion of the left and right coronary cusps. (C) Bicuspid aortic valve, fusion of the right and noncoronary cusps.
(D) Bicuspid aortic valve, fusion of the left and noncoronary cusps.
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Figure 2. Macroscopic illustration of a bicuspid aortic valve with the fusion of the right and noncoronary cusps (left
image) and a dilated ascending aorta (right image). A: Non coronary cusp, B: Right coronary cusp, C: Left coronary
cusp, D: Raphé, E: Ascending aorta (dilated).
3. Morphologenesis
The embryogenesis of BAV is still not fully understood. It seems that both genetic predispo‐
sition and environmental factors, which could influence the valve morphogenesis, play an
important role in the pathogenesis of BAV disease. Initially, the major factor in the formation
of BAV is the fusion of the two cusps at the early foundation of the valvulogenesis [22]. The
valve morphogenesis occurs in the early stage of foetal development. The heart is one of the
first organs to develop through the specification and migration of the anterior lateral plate
mesoderm cells which later forms the cardiac crescent [23]. At 3 weeks of gestation in humans,
the cardiac progenitors migrate along the ventral midline where they fuse and form a linear
heart tube. This beating heart tube is composed of an inner endocardial cell layer which is
separated by the extracellular matrix (ECM). Cardiac looping occurs at 4 to 5 weeks of gestation
which brings the atrial region of the linear tube into the posterior position of the common
ventricles. This is followed by the increase of ECM production which causes the tissue to swell
at several areas of the primitive heart, which leads to the formation of the endocardial cushions
at the outflow tract (OFT) and atrioventricular (AV) canal. The inner endocardial cells
transform into mesenchymal cells, also known as the epithelial-to-mesenchymal transforma‐
tion (EMT). EMT initiates the formation of the aortic valve in the OFT. Afterwards, the cushions
undergo massive cell proliferation, as a result growing towards each other with cushion fusion
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being the outcome. Subsequently, the endocardial cushions develop into thin protruding
leaflets that are composed of endocardial cells and ECM which remodels the valves. This
complex development is reliant on apoptosis, ECM remodeling and cell differentiation. The
main contributors for the aortic valve in the OFT are the mesenchymal cells that reach the OFT
cushions in association with the endocardial derived mesenchymal cells [24, 25]. Therefore,
any disorder in the endocardial cushion development could lead to potential valve disorder
including BAV. A disturbance in the neural crest migration which could lead to the fusion of
the aortic valve cushions is thought to be a possible embryological explanation for the
pathogenesis of BAV disease [22, 26-28]. Several aneurysms which originate from the neural
crest including intracranial aneurysms, aortic aneurysms, and cervicocephalic aneurysm have
also been observed in patients with BAV disease [29, 30]. Endothelial nitric oxide synthase is
a vital protein for valve formation during embryogenesis. Knockout mice lacking this protein
showed a high predisposition for BAV due to the fact that malformation in this protein could
lead to disturbance of the intricate cell signals which are essential for valvulogenesis [31].
Moreover, it seems that L-R BAV and R-N BAV have different etiological attributes and
genotypes. The pathogenesis of R-N BAV is most likely the result of morphogenetic defect
which occurs before the OFT septation and is dependent on an aggravated nitric oxide–
dependent epithelial-to-mesenchymal transformation. In contrast, L-R BAV is most probably
the outcome from the anomalous septation of the proximal portion of the OFT which is caused
by distorted activities of neural crest cells [32].
4. Genetics
Genetic burden also seem to contribute to the pathogenesis of BAV disease. It appears that
BAV disease has a male-to-female ratio of roughly 3:1 [1-4]. Although some anatomical risk
factors have been described, little is known about BAV disease with respect to the genetic
insight of calcification process and why patients with BAV disease develop aortic valve
calcification including stenosis at an earlier age compared with degenerative tricuspid valve.
Chromosomal linkage with BAV disease has been discovered in chromosomal regions 5q, 13q
and 18q [36]. Genetic mutations in the NOTCH 1 gene, which is situated at chromosome 9q
seems to be one of the major genetic contributors in the pathogenesis of BAV disease. NOTCH
1 gene contributes to the pathogenesis of BAV disease through the pathological acceleration
of aortic valvular calcium deposition by the increase of the osteogenesis due to the abnormal‐
ities in the signalling pathways [37]. Also, genetic mutations in the ACTA2 gene which is
located at chromosome 10q, is associated not only with BAV disease, but also with familial
thoracic aortic aneurysms [38]. ACTA2 gene encodes for the smooth muscle protein α-actin
which is an important element of the contractile apparatus. Several familial clusters associated
with BAV disease with an estimated prevalence of 24% of aortic valve disorder were found in
relatives with more than one member with aortic valve disorder [33]. Additionally, an
estimated BAV disease prevalence of up to 9% in first-degree family members of patients with
BAV disease has been reported [34, 35]. Based on this known data, it is advisable for first-
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degree family members of BAV patients to receive an echocardiographic screening to exclude
any potential congenital heart disease including thoracic aortic aneurysms [39, 67, 68].
5. Congenital associated cardiovascular malformations
Although the vast majority of BAV disease are isolated cases, patients with BAV could also
present with additional congenital cardiovascular malformations [40-43]. BAV associated
anomalies are illustrated in Table 1. Whereas most associated anomalies need treatment early
in life, BAV often contributes to morbidity at an older age. COA and Turner Syndrome will be
further discussed in this chapter.
5.1. Coarctation of the aorta
COA is a commonly seen congenital abnormality with an incidence of 50 of 100.000 births,
whereby the aorta is narrowed in the region where the ductus arteriosus enters [figure 3]. COA
can present itself as a simple or complex COA with simple COA referring to COA being an
isolated defect and complex COA referring to a combination of COA with other cardiac defects.
Congenital BAV is present in around 57% of the COA cases [44]. In the vast majority of the
cases, COA in combination with BAV is observed with the fusion of left and right coronary
cusps [9]. Patients with both BAV and COA have an increased risk for developing several aortic
complications including aortic dissection, AS, AR, and aortic aneurysms [16, 44, 46, 49]. The
overwhelming majority of BAV patients present with a L-R BAV (66-90%) [9, 135, 136].
Patients  with both BAV and COA receive surgical  intervention at  a  relative young age.
Surgical  options,  mostly  depending of  the  type of  lesion include bypass  of  the  coarcta‐
tion,  patch  aortoplasty,  aneurysm replacement,  arch  and  descending  aorta  replacement,
subclavian artery patch aortoplasty, tube graft replacement, ascending aorta–to– descend‐
ing aorta bypass or 2-stage combined BAV surgery [69].  Endovascular balloon dilatation
and  stent  placement  are  currently  becoming  successful  novel  interventional  options  to
conventional open surgical  treatment [70].  Around 11% to 14% of the patients require a
reoperation somewhere in the adulthood [50]. A large cohort study showed that up to 41%
of the patients who had a COA required a valve related re-operation [9]. Thus, long-term
follow-up in (all) patients with COA including the evaluation of the function of the aortic
valve,  but also to trace re-coarctation and dilatation of the ascending aorta with routine
MRI or echocardiographic evaluation is obligatory.
5.2. Turner Syndrome
Turner Syndrome is a gonadal dysgenesis with complete or partial absence of one of the
X  chromosome.  Cardiovascular  defects  are  frequently  observed  in  Turner  Syndrome
patients.  Turner Syndrome is  characterized as neck webbing,  short  stature,  low hairline,
and a shield-like chest. BAV disease is the most frequently seen cardiovascular abnormali‐
ty  in  Turner  Syndrome  patients  [51,  52].  In  Turner  Syndrome  patients,  cardiovascular
abnormalities are often the primary cause of mortality including the increase risk of aortic
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dissection  due  to  aortic  root  dilatation  and therefore  responsible  for  a  much lower  life
expectancy in this subgroup of BAV disease [53, 54]. Due to the relative small body size,
Turner Syndrome patients require an elective ascending aortic aneurysm replacement at a
much smaller absolute size [54]. Moreover, it should be noted that the aortic size has to be
properly indexed to the body surface area. Therefore, proper follow-up and evaluation of
the cardiovascular lesions including imaging of the heart and the aorta for evidence of BAV
disease or  dilatation of  the ascending aorta  is  mandatory.  When imaging appears  to  be
without any lesions and there are no additional risk factors for aortic dissection present, a
repeated imaging should be conducted every 5 to 10 years or otherwise clinically indicat‐
ed.  In contrast,  when abnormal imaging is  present,  regular  imaging at  smaller  intervals
should be made with echocardiography or CMRI [67].
Table 1. Known cardiovascular abnormalities related to BAV disease.
Figure 3. Sagittal plane cardiac magnetic resonance imaging illustrating coarctation of the aorta. Typical post ductal
stenosis (arrow).
Calcific Aortic Valve Disease310
6. Diagnosis
6.1. Clinical examination
AS or AR can present themselves with significant symptoms in patients with BAV disease
during activity, stress or rest including angina, shortness of breath, syncope or dizziness. In
many cases, clinical examination reveals an ejection sound during auscultation at the apex.
When AS is present, an ejection click can be often heard at the S1. The S2 is often simultaneously
with P2 when AS is present. A diastolic murmur can often be heard when an AR is present.
Heart failure of unknown cause could also be present during clinical examination. The ejection
sound in BAV patients is most likely associated with anterior movement of the dome shaped
BAV, and in rare cases heart failure could also be present during clinical examination in case
of rapid deterioration [55]. AS, mitral valve prolapsed, AR, and COA are several associated
pathological findings which have to be considered with BAV when a murmer is present.
6.2. Echocardiography
The current golden standards for diagnosing, surveilling and monitoring BAV disease are
echocardiography and cardiac magnetic resonance imaging (CMRI) [39].
Both transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) can
be used in the diagnosis of BAV disease. TTE has a sensitivity of 78% to 87% and a specificity
of 91% to 96% for the diagnosis of BAV disease whereas TEE has a sensitivity and specificity
of 87% and 96%, respectively [56, 57, 58]. However, up to 25% of TTE have non-diagnostic
findings for aortic valve morphology due to severe valvular calcification [57].
The features of BAV on a TTE include systolic doming, an eccentric closure line in the para‐
sternal long axis views, presence of a single commissural line in the diastolic phase with the
occurrence of two cusps and the occurrence of two commisures in the parasternal short axis
views [figure 4] [59, 60].
Moreover, both preoperative echocardiography and intraoperative TEE are essential for
surgical preparation. When BAV disease is present, the degree of AS and AR should be
determined with the help of Doppler analysis. After determining the severity of the AR, to
ascertain the indication for surgery, especially TEE is needed to clarify the mechanisms that
are responsible for AR. This is required to estimate the chance of successful repair and
indispensible in surgical preparation. Moreover, any associated cardiovascular abnormalities
or complications should be considered. Aortic diameters should therefore also be measured
at several levels including valvular insertion, sinuses of Valsalva, sino-tubular junction and
the ascending aorta. It should also be noted that in order to measure the severity of the AS by
echocardiography- Doppler analysis, the aortic valve area and mean gradient should be
applied rather than measuring only on peak systolic gradient, sequentially to prevent overes‐
timation of the severity of the AS [39]. Also, aortic valve area should always be indexed to
body surface area in order to correct for different habitus and body sizes, especially in Turner
Syndrome patients [39, 54].
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6.3. Cardiac magnetic resolution imaging
CMRI as a noninvasive diagnostic tool appears to have a high diagnostic sensitivity and
specificity. CMRI showed a sensitivity of 100% and a specificity of 95% with steady state free-
precession (SSFP) cine [61]. It seems that CMRI is more reliable than the standard TTE in
diagnosing BAV [Figure 5]. When TTE is found to be non-diagnostic for aortic valve mor‐
phology, particularly in patients with severe AS, CMRI can be conducted as a complementary
test [62].
When the diagnostic results of AR with the use of echocardiography is indefinite or at
borderline, CMRI can be used to quantify the AR more accurately [39]. In addition, the valve
can be visualized with any correlated lesion of the ascending aorta. This could be used for
proper evaluation of the entire aortic and to prepare complex surgical interventions for both
the aorta valve and the surrounding cardiovascular structures including the ascending aorta
and the aortic root. Of importance, all patients with evidence of BAV should have the aortic
root and ascending aorta inspected for indication of aortic dilatation with echocardiography
or MRI [67].
Figure 4. (A) Transthoracic echocardiography short axis view illustrating a normal tricuspid aortic valve. (B) Trans‐
thoracic echocardiography short axis view illustrating a bicuspid aortic valve with fusion of the left and right coronary
cusps. (C) Transthoracic echocardiography long axis view illustrating a dilated ascending aorta (Arrow). (D) Transthora‐
cic echocardiography short axis view illustrating a bicuspid aortic valve with fusion of the right and non coronary coro‐
nary cusps. (E) Transthoracic echocardiography short axis view illustrating a severe calcified bicuspid aortic valve with
fusion of the right and non coronary coronary cusps. (F) Transthoracic echocardiography long axis view illustrating a
severe calcified bicuspid aortic valve.
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Figure 5. Panel (A, B) Cardiac magnetic resonance imaging in the axial plane illustrating a normal tricuspid valve in the
diastolic (A) and systolic phase (B). (Panel C, D) Bicuspid aortic valve with fusion of the right coronary cusp and the non
coronary cusp in the diastolic (C) and systolic (D) phase. (Panel E) Sagittal plane illustrating a dilatation of the ascend‐
ing aorta (Arrow).
7. Complications associated with BAV
7.1. Aortic stenosis
Up to 50% of the adults who present with AS show evidence of BAV disease [71]. BAV
degeneration is due to both fibrosis and calcification and is age related [16, 72, 73]. Addition‐
ally, the incidence of BAV related AS that is observed in patients with the age of under 60 years,
60 to 75 years, and more than 75 years are 59%, 40% and 32%, respectively [74].
Patients with BAV generally require AVR 5 years earlier compared with the patients who have
an AS of the tricuspid valve [75]. Three-quarters of the patient with BAV who underwent AVR
showed to have an isolated AS [7]. Both fibrosis and cusp calcifications occur in an accelerated
pattern in BAV compared with tricuspid aortic valve [Figure 4, E &F] [76]. Moreover, several
valve related factors seem to accelerate the calcification in BAV including larger sized cusp,
presence of raphé and the overall BAV anatomy. It seems that sclerosis of the aortic valve starts
in the second decade whereas calcification tends to develop around the fourth decade onwards
with a 18 mmHg per decade increase of the average aortic valve gradient [75, 12]. Both R-N
BAVs and asymmetrical sized cusps seem to contribute to the acceleration of the stenosis due
to the progressive calcification and fibrosis with 27 mm Hg per decade [9, 45, 12]. It has to be
noted that smoking and a poor lipid panel are both modifiable independent risk factors that
could have a great impact on BAV degeneration [77]. In children, BAV with stenosis can
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sometimes be treated with balloon valvuloplasty whereas in other cases surgical commissur‐
otomy is indicated [75, 78-80]. Severe fibrosis of the cusp tissue and calcified degeneration,
which is found in the older population, make surgical repair difficult or impossible in most
cases. AVR is therefore the primary surgical treatment of BAV with severe stenosis in adults.
7.2. Aortic regurgitation
AR most often involves patients with a young age and is less frequently seen than AS with
prevalence ranging from 7% to 20% [15, 78, 81, 82]. AR can occur in the isolated form due to
the prolapse of one of the cusps, but it could also occur due to and in combination with
endocarditis, COA, and proximal aortic root dilatation [16, 25]. The presence of AR could have
severe consequences for the patient’s morbidity including the increased risk of heart failure,
endocarditis and arrhythmia [80]. Aortic root dilatation is found in nearly half of the young
adults with BAV disease, thus increasing the risk for AR [83]. In selected cases, patients with
BAV disease and isolated AR can be a candidate for aortic valve repair [84].
7.3. Aortic dilatation and dissection
BAV disease is linked with dilatation of the proximal aortic root and ascending aorta and
develops independently from stenotic or regurgitant aortic valvular lesions [91]. This process
eventually leads to dissection or rupture of the aortic wall with potentially fatal consequences.
Several molecular pathways have been discovered, possibly of genetic basis, which suggest
that histopathologic modifications in the extracellular matrix of the dilated proximal aortic
wall are a key pathogenesis of aortic dilatation in BAV patients. This includes the loss of smooth
muscle cells, cystic medial necrosis and elastic fibre fragmentation [92, 93]. Furthermore,
morphometric analysis of the aortic media showed deformities of the elastic lamellae and less
elastic tissue in BAV patients in comparison with patients with tricuspid aortic valves [93, 94].
It appears that apoptosis is a key mechanism for the loss of the smooth muscle cells in the
ascending aorta of BAV patients which can eventually lead to cardiovascular complications
[95, 96, 97]. In addition, regarding the remodeling of the extracellular matrix, fibrillin-1
microfibrils were significantly reduced while the matrix metalloproteinase-2 and -9 activities
were significantly increased in the aortic media of BAV patients. When fibrillin-1 deficiency is
present, the release of enzymes, also known as matrix metalloproteinases, will increase and
weaken the aortic wall by degrading elastic matrix components, thus resulting in aortic
dilatation and degeneration [98, 99, 100].
Approximately 40% of the BAV cases develop proximal aortic root dilatation while an
estimation of 6% lifetime risk is observed for aortic dissection [101].
Risk factors for developing an adverse aortic complications such as rupture or dissection in
BAV patients include positive family history of aortic aneurism, dilatation of the sinotubular
junction, the presence of AR, young age (<40 years), and aortic dilatation greater than 50 mm
[101, 102]. Aortic dissection occurs most commonly in young adults with an asymptomatic
medical history of BAV. A severe risk for aortic dissection is present when the aortic diameter
surpasses 50 mm. [102]. When BAV is present in combination with aortic dilatation, the risk
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of aortic dissection is increased 9 fold compared with tricuspid valve cases [16]. Additionally,
the area of the aortic dilation also varies among BAV patients. Some patients have a dilatation
of the proximal ascending aorta dilation, while others have a dilation of the sinuses of Valsalva
and yet other patients present with a dilatation of the transverse arch or a combination of these
locations [103].
Aortic dilatation of the sinuses of Valsalva is often seen in patients with L-R BAV, whereas
patients with R-N BAV present with the dilatation of the ascending aorta [10]. Of note, aortic
dilatation and thoracic aortic aneurysm formation could also occur in BAV patients or related
family members with the absence of significant valve pathology in the form of AS or AR [51, 68].
7.4. Infective endocarditis
Infective endocarditis is a condition high risk on mortality and morbidity which effects 10%
to 30% of the BAV patients with actual risk assessment of 0.3% to 2% per patient-years in adults.
Although these estimations are based on selected cases, the true incidence of BAV related
infective endocarditis is most likely lower. [16, 85, 86]. Moreover, one-fourth of the infective
endocarditis cases are a complication due to BAV. Infective endocarditis is frequently seen in
young adults and adolescents rather than in elderly patients, particularly the male gender [16].
Almost three-quarters of the endocarditis related BAV cases are caused by Viridans streptococ‐
ci and Staphylococci [87]. Poor dental hygiene, presence of a dialysis shunt and venous catheters
are major independent risk factors for developing infective endocarditis due to the high risk
of contamination [88]. Several complications due to infective endocarditis in BAV patient can
occur including heart failure, the formation of myocardial or valvular abscess, and mortality
within 6 month after hospital admission [89]. Antibiotic prophylaxis is nowadays no longer
recommended for patients with BAV and with calcified aortic stenosis, except in BAV patients
with a prior history of infective endocarditis, prosthetic heart valves, or prosthetic material
used for heart valve repair [90].
8. Interventions
Surgical intervention is the key treatment option for patients with symptomatic BAV disease
and the related aortic dilatation. Several factors are dependent on the surgical treatment
management including the location and the severity of the aortic dilatation and the perform‐
ance status of BAV.
8.1. Surgical indications for aortic valve repair/replacement
Surgical intervention for patients with BAV disease occurs at a relative earlier age than for
degenerative tricuspid aortic valve disease [71]. In a study of 212 asymptomatic community
residents, an average age for surgical intervention was reported for BAV disease versus
degenerative tricuspid valve disease of 40± 20 years and 67 ± 16 years, respectively [85]. In
Scheme 1, indications for surgical intervention in patients with BAV disease including AR, AS
and/or proximal ascending aorta dilation are described. In adults with BAV disease, surgical
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intervention in the form of AVR is recommended when severe AS, chronic AR and left ventricle
dysfunction (LV) with a LV ejection fraction (EF) of < 50% is present. Furthermore, adolescents
and young adults with severe AR who have developing symptoms, persistent LV dysfunction
with LV EF < 50%, or progressive LV dilatation, are also suitable candidates for AVR [39].
Several factors has to be kept in mind when choosing a patient tailored intervention namely,
the risk for reoperation with bioprosthetic valves due to valve degeneration, and the necessity
of lifelong anticoagulation with mechanical valve replacement. In athletic patients, bleeding
risks due to chronic use of anticoagulation should be discussed, as well as the potential risk of
teratogenic dangers of warfarine for women who desire pregnancy in the future. The discus‐
sion of the risk and benefits for both procedures is therefore mandatory.
Scheme 1. Indication for cardiac surgical intervention in patients with bicuspid aortic valve disease including aortic
regurgitation (AR), aortic stenosis (AS), and/or aortic dilatation. LVEF = left ventricle ejection fraction; LV dilatation =
Left ventricle dilatation (End-systolic diameter > 55mm or end-diastolic diameter > 75 mm); Clinical symptoms include
dyspnoea, angina, or syncope; Severe AS = jet velocity > 4 m/s, mean gradient. 40 mm Hg, valve area < 1 cm²; severe
AR = jet width < 65% of LOVT, vena contracta width > 0.6 cm, regurgitant volume > 60 mL, regurgitant fraction >
60%, regurgitant orifice area >0.3 cm². AVR = aortic valve replacement (Data derived from Bonow et al. [39]).
8.2. Surgical indications for ascending aorta dilation
As mentioned earlier, BAV disease is associated with aortic dilatation. BAV patients with the
presence of AR or AS should receive surgical intervention of the ascending aorta when an
aortic diameter of ≥ 45 mm is present. Conversely, BAV patients with absence of additional
risk factors and co morbidities should receive surgical intervention at an aortic root or
ascending aorta dilatation of ≥ 50 mm or a aortic dilatation expansion rate of ≥ 5 mm per year
[39]. However, it seems that aortic size relative to body size could be a more superior novel
technique to define high risk patients requiring surgical intervention [104]. Proper routine
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evaluation of the aortic root and ascending aorta is therefore mandatory in patients with BAV
with echocardiography or MRI to determine the potential presence of an aortic dilatation [67].
8.3. Pharmacological treatment options
Systematic high blood pressure is an independent risk factor for developing complications
including aorta dissection in patients with stenotic BAV with aortic root dilatation. Β-blocker
therapy is therefore advisable for patients with BAV disease [39]. Moreover, osteogenic and
proteolytic activities,which is a precursor to atherosclerotic and calcified degenerative AS,
have been revealed in early aortic valve disease with the use of multimodality molecular
imaging [115]. However, lipid lowering therapy didn’t reduce calcific valve progression with
respect to moderate to severe AS [116, 134]. Although, little evidence have acknowledged the
beneficial use of statins in BAV disease, patients with BAV disease who have risk factors for
atherosclerosis should receive statins with the purpose of reducing the degenerative risk in
the aorta and potentially preventing atherosclerosis. Long-term vasodilator therapy is only
recommended in BAV patients with AR if systematic hypertension is present [39]. Despite this,
there is currently no concrete evidence suggesting that pharmacological treatments could alter
the natural history or halt the development BAV calcifiation.
Scheme 2. Cardiac surgical options for aortic dilatation in patients with bicuspid aortic valve disease. AR = aortic re‐
gurgitation, AS = Aortic stenosis.
8.4. Surgical options
The surgical options are illustrated in Scheme 2 for BAV disease with aortic dilatation. When
patients require an intervention of the aortic valve with an aortic diameter < 45 mm, the main
surgical option is a bioprosthetic AVR, mechanical AVR, the Ross procedure which is contra‐
indicated in older patients with BAV and onset of aortic dilatation, or aortic valve repair in
selected cases of AR. In patients with > 45 mm ascending aorta root dilatation with significant
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aortic valve pathology, aortic root replacement therapy, (Bentall procedure) is the main
surgical option.
8.5. Valve repair
Surgical repair can be considered when BAV disease is presented without any significant signs
of calcification or valve thickening [105]. Several surgical repair options are available including
raphé resection with or without leaflet placation, shortening or reinforcement of the free
margin, augmentation of the pericardial patch cusp, aortic root repair, and subcommissural
annuloplasty [105, 106]. Patients with BAV disease show evidence of sclerosis after the second
decade and calcification associated with increasing stenosis at the fourth decade [12, 75]. This
raises the question with respect to valve sparing replacement of a dilated aorta, especially in
young patients. Although, it appears that the need for reoperation is greater in the surgical
repair group for AR, this surgical option still remains attractive in both young adults with AR
and women with BAV disease who want to become pregnant.
8.6. Ross procedure
The Ross procedure, also known as the pulmonary autograft, is a cardiac surgical procedure
in which the pathological aortic valve is replaced with a patient’s own pulmonary valve after
which a pulmonary allograft is performed with a valve from a donor which is then used to
substitute the patient’s own pulmonary valve. Several benefits have been reported with the
Ross procedure including the absence of anticoagulation, reduced endocarditis risk, and
encouraging valve hemodynamic gradients [107]. However, major concerns have been raised
including the most important concern regarding the durability of the autograft and allograft.
In addition, another key concern is that histopathologic alterations of the pulmonary trunk
may occur, after which the pulmonary trunk can show resemblances of the proximal aorta,
thus increasing the risk for aortic aneurysms with a reoperation being the most likely end result
[108]. The Ross procedure has no beneficial benefits over conventional AVR in adult patients
with respect to hemodynamics or postoperative outcomes. Nevertheless, the Ross procedure
offers adolescents, young adults and women with BAV disease who want to become pregnant,
an adequate solution in the first decade after the operation. However, limitation with respect
to the durability is evident by the end of the first postoperative decade, especially in younger
patients [109]. Ross procedure in the setting of BAV disease still remains controversial and
should only be performed in selected cases in specialized centres.
8.7. Bentall procedure
Due to the risk of aortic dilatation in patients with BAV disease, the majority of the surgeons
evaluate the option of reinforcing or replace the ascending aorta with at the time of the valve
surgery. The Bentall procedure is a widely used surgical procedure for patients with BAV and
aortic root dilatation. This procedure includes the replacement of the aortic valve, aortic root
and ascending aorta with the reimplantation of the coronary arteries [110]. Excellent long-term
results have been observed with the Bentall procedure with respect to survival in patients with
aortic valve disease and aorta dilatation [111]. This procedure is a suitable intervention in older
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patients with severe BAV pathology with normal-sized sinuses and dilatation of the supra‐
coronary ascending aorta.
8.8. Yacoub and David procedure
Valve sparing aortic root replacement procedure may be an alternative to Bentall procedures
in selected BAV patients such as young adults who present with aortic root lesion with
normally functioning aortic valve including the absence of calcified aortic valves, multileaflet
prolapsed and annular dilatation [112]. Two variations for this procedure have been described
namely the remodeling (Yacoub) procedure and the re-implantation (David) procedure [113,
114]. The coronary artery ostia are removed as buttons in both procedures followed by
reimplantation of a Dacron aortic graft with additional leaflet repair, if required. However, in
the David procedure, the aortic root is mobilized to below the plane of the ventriculo-aortic
junction followed by a Dacron graft replacement which is telescoped down outside the aortic
root to provide a functional aortic annuloplasty. It seems that there is no significant difference
between these two procedures in BAV patients. Valve sparing procedures are more surgically
changeling than the traditional Bentall procedure and are only conducted in specialized aortic
centres. When tubular ascending aorta dilatation is present with no root or valve pathology,
supracoronary ascending aortic replacement is required in BAV patients. When valve pathol‐
ogy is present with this anatomical lesion, a Wheat procedure should be preformed. This
procedure includes separate AVR or repair leaving the sinus segment intact. However, due to
the fact that in most cases sclerosis of the aortic valve starts in the second decade and calcifi‐
cation begins to develop around the fourth decade, serious consideration have to be made with
respect to valve-sparing replacement of a dilated aorta in young adults with normally
functioning BAV [12, 75].
8.9. Balloon valvuloplasty
Due to the growth of adolescents during childhood, prosthetic valve insertion is unsatisfactory.
Balloon valvuloplasty is therefore a successful treatment option because of the fact the aortic
valve is not calcified at this age of the child and the fact that valvuloplasty disrupts the
commissural fusion and reduces the obstruction when implemented. Balloon valvuloplasty is
indicated in young adults and adolescents without significantly calcified BAV and no AR who
experience symptoms with a peak-to-peak gradients of > 50 mm Hg. Also, asymptomatic
adolescents who develop ST- or T wave changes with exercise or rest or demonstrate a peak-
to-peak gradient of > 60 mm Hg should be considered candidates for balloon valvuloplasty.
Additional indications for balloon valvuloplasty are asymptomatic adolescent or young adult
who are interested in sport activities or becoming pregnant with a peak-to-peak gradient > 50
mm Hg. When severe AR is evident after balloon valvulplasty, AVR should be considered.
Conversely, valvuloplasty is seldom performed in old adults due to often severe calcification
of the aortic valve [39, 86]. However, balloon valvuloplasty should be considered as a bridge
to surgery in adults with AS who have a high risk for AVR, who are hemodynamically unstable,
or when AVR is not possible to perform due to secondary co morbidities. Excellent mid-term
results have been observed after balloon valvuloplasty at experienced centres [117-119].
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8.10. Transcatheter aortic valve implantation
Transcatheter aortic valve implantation (TAVI) is a novel minimally invasive technique
indicated for patients who are contraindicated for cardiac surgery due to associated comor‐
bilities or who have a high risk of perioperative mortality. TAVI is an alternative treatment for
patients with valve disease in which a valve replacement is introduced through the femoral
artery via a small incision or in some cases, an incision into the chest after which the catheter
is inserted into the left ventricular apex, also known as the transapical approach. Other
methods include subclavian in which the catheter is inserted beneath the collar bone and direct
aortic incision in which the catheter is inserted directly into the aorta via a minimally invasive
incision in the chest [120]. Due to the asymmetric anatomy which is observed with BAV disease,
the TAVI device could potentially be affected to a noncircular expansion, thus creating an
elevated risk of paravalvular leak [121]. Due to this major concern, BAV is considered a
contraindication with respect to TAVI. BAV have been overall excluded in all the major TAVI
trials in which little clinical experience is now known with regard to TAVI in BAV cases.
However, several centres showed acceptable results in selected BAV patients with AS
[121-123]. A high risk of suboptimal device seating has been observed in BAV patients with
asymmetric valvular anatomy, AR, and bulky leaflets. Whether novel valve designs could
improve TAVI performance in the BAV group, still remains uncertain.
9. Surveillance
All patients with BAV disease whether AS, AR, operated or not, should receive lifelong serial
follow-up depending on symptoms and degree of the functional disorder. Moreover, serial
follow-up with imaging assessment with respect to the cardiac and aortic anatomy including
valve function, LV function, diameter of both ascending aorta, sinotublular junction, sinuses
of Valsvalva and the annulus should be performed in BAV patients regardless the severity of
the pathology. TTE is a reliable diagnostic tool to monitor the aortic valve and ascending aorta.
However, it should be noted that it is difficult to obtain adequate imaging with the TTE
regarding the mid and distal ascending aorta and arch, especially in BAV patients with large
body index, in which MRI or CT scan should be used.
The occurrence of imaging should depend on the size of the aortic root at the initial assessment.
If the aortic root is < 40 mm with no clinical symptom alternations, the ascending aorta should
be reimaged every 2 years. Whereas, if the aortic root is ≥ 40 mm, it is should be reimaged
annually or even more often if progression of the aortic root dilatation is present or whenever
a change in clinical symptoms and/or findings occur with echocardiography or MRI [39]. Also
of importance, first degree family members of patients with BAV disease should receive
echocardiographic screening due to the increased risk of cardiovascular abnormalities [39].
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10. Sport participation
The vast majority of young adults with BAV disease are asymptomatic. Little is known
regarding the risks of aortic dissection and sudden cardiac death in young adults with BAV
who participate in athletic activity. Also, the severity of the valve pathology and aortic root
dilatation in this subgroup of BAV patients influence the clinical decision making with respect
to strategy and recommendations for sport activity.
No restrictions are necessary with respect to BAV patients with an athletic lifestyle who present
with a mild AS. However, asymptomatic BAV patients with moderate AS can only conduct
low-intensity athletic competitive activities. Exercise stress testing is mandatory for BAV
patients with moderate AS to detect any additional risk factors including unusual blood
pressure during exercise, onset of symptoms during exercise or pathological arrhythmias,
which could eventually alter the clinical strategy and recommendations. In addition, BAV
patients with symptomatic moderate or severe AS should receive immediate surgical inter‐
vention and should therefore not participate in any form of competitive sport activities upon
surgery [124].
BAV patients with mild enlargement of the left ventricular end-diastolic dimension and mild
to moderate AR have no restriction in participating in all forms of athletic activity. Also in this
case, an exercise stress testing should be performed to estimate the risk. Patients with BAV
disease who have a definite LV enlargement of ≥ 60 mm, pulmonary hypertension, or any
degree of LV systolic dysfunction at rest should avoid any form of competitive sport activities
[124]. BAV patients who underwent an AVR should avoid any form of contact sport.
Also, BAV patients with severe AR and left ventricular end-diastolic diameter > 65 mm should
avoid any form of competitive sport activities. This also includes BAV patients with mild-to
moderate AR associated with positive symptoms for valve disease [124]. Young adults with
uncalcified AS with a peak-to-peak gradient > 50 mm Hg should who play competitive sports
are candidates for aortic balloon valvuloplasty [39]. The recommendation for sport activity for
BAV patients with respect to dilatation of the proximal aortic root depends on the level of
severity the aortic dilatation. BAV patients with an aortic root diameter of 40 to 45 mm should
only perform low to moderate intensity sport activity and preferably avoid any form of contact
sport. Moreover, BAV patients with an aortic root diameter of > 45 mm are allowed to conduct
low-intensity sport activity due to due to the potential risk of aortic root dissection [125].
11. Pregnancy
Although, the vast majority of pregnancies with congenital AS go through labour uncompli‐
cated, some pregnancies with severe AS have a higher risk rate of morbidity, although the
mortality rates still remains rare [126, 127].
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Severe AS is not well tolerated in pregnant women and is associated with high peripartum
complications [75]. Around one-third of the pregnant women with maternal congenital AS
showed clinical complications with a significant rate of abortion [128]. Of note, it is recom‐
mended that women with AS who are considering becoming pregnant receive prepregnancy
counselling [39].
Nevertheless, mild-to-moderate AS is well tolerated by pregnant women and show no
complications with respect to labour compared to pregnant women with severe AS who had
a deterioration rate of 10% [126].
Asymptomatic severe AR is well endured by pregnant women unlike severe AS [129]. A
possible explanation for this phenomenon is because of pregnancy related physiologic changes
which presents with an afterload decrease and heart rate increase with a shortening of the
diastole, thus reducing the level of AR.
Of note, several recommendations has to be considered in pregnant women with severe BAV
pathology with symptoms including pre-pregnancy counselling, foetal echocardiography
during the second trimester to investigate whether cardiac defects is present in the foetus, and
close cardiac follow-up in the form of echocardiography to monitor changes in symptoms and
further valve deterioration [39]. Several side effects have been reported when cardiac surgery
requiring cardiopulmonary bypass is used including the potential risk of fetal distress, fetal
wastage and growth retardation [130, 131]. Therefore, it should be noted that women with a
high risk for complications during pregnancy should abstain from pregnancy until the valve
pathology is properly surgically treated [124]. Moreover, parents should receive proper clinical
counselling with respect to the genetic predisposition and the risk of congenital cardiac defect
in their children [132].
Encouraging results have been observed with the balloon valvuloplasty during pregnancy
including successful completion of the pregnancy [133]. However, concerns have been raised
regarding symptomatic AR after balloon valvuloplasty which is also a burden for pregnant
patients. Therefore, balloon valvuloplasty should be considered as a bridge to surgery in
pregnant women with severe AS. When an unplanned pregnancy occurs in women with severe
aortic pathology with symptoms, physical restriction with close cardiac follow-up are obli‐
gated. Furthermore, vasodilatation and volume depletion medicine should be avoided at all
time. Due to the compression of the inferior vena cava by the gravid uterus, it is recommended
that the delivery should be performed in the left lateral decubitus position.
12. Conclusion
BAV disease is a frequently seen congenital cardiac defect, complicated with proximal
thoracic aortic aneurysm and associated with other cardiovascular malformations including
Turner Syndrome and COA. Although little is known about the pathogenesis of BAV dis‐
Calcific Aortic Valve Disease322
ease, it seems that BAV disease is linked with both genetic predisposition and defects in the
early valvulogenesis. Further investigation is required with respect to the basic genetic and
embryological defects associated with BAV disease and the proximal aortic dilatation in‐
cluding the cellular mechanisms and signalling pathways. This will give us more under‐
standing regarding the background of the degeneration and calcification of the bicuspid
valve, and the development of aortic aneurysm. This could offer new pharmacological tar‐
gets to prevent calcification, degeneration and aortic dilatation.
The dilatation of the proximal thoracic aorta may lead to complications including ascending
aortic aneurysm and dissection. Early detection, vigilant patient assessment and frequent
follow-up by imaging including echocardiography, CT and CMRI can potentially persevere
both long-term survival and quality of life in patients affected by BAV disease.
Several interventional options are available for patients with BAV disease and aortic dilata‐
tion. Balloon valvuloplasty is indicated in young adults and adolescents without significant‐
ly BAV calcification. Surgical repair (Yacoub and David procedure) should be considered
when BAV disease is presented without any significant signs of calcification or valve thick‐
ening. In contrast, when calcified BAV disease is present, AVR, Bentall procedure or Ross
procedure is necessary. Although in some cases these procedures are performed in valves
without calcification. TAVI is relatively contraindicated due to the asymmetric anatomy
which is observed patients with BAV disease. The TAVI device could potentially be affected
to a noncircular expansion with the risk of paravalvular leak. BAV patients were excluded
in the major TAVI studies. Future research should focus on novel valve designs.
Despite the fact that limited data exist with respect to prophylactic interventions, BAV dis‐
ease associated aortic dilatation with absence of additional risk factors and co morbidities is
indicated when the diameter is ≥ 50 mm or an aortic dilatation expansion rate of ≥ 5 mm per
year. In patients with BAV disease with additional risk factors, such as COA, Turner Syn‐
drome and a family history of aortic dissection, replacement should be considered when a
diameter of ≥ 45 mm is present. Patients with symptoms of BAV disease due to AR or AS, or
asymptomatic LV dysfunction all require surgery. If the ascending aorta exceeds 45 mm, the
root should be replaced as well. Valve sparing aortic root replacement procedure is recom‐
mended in young patients who present with aortic root lesion with normally functioning
aortic valve including the absence of calcified aortic valves, multileaflet prolapsed and an‐
nular dilatation. Future studies are mandatory, not only to predict the optimal timing for
AVR when symptoms occur, but also to investigate whether prophylactic intervention of the
ascending aorta at the time of AVR is necessary. Also, additional studies are required to de‐
termine the risks factors for aortic dissection and the optimal diameter at which replacement
of the ascending aorta should be performed in patients with BAV disease. Future studies
should also focus on sudden cardiac death in young adults with BAV disease who partici‐
pate in athletic activity.
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